Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMZ6VEY)

Drug Name
Sulfacetamide Drug Info
Synonyms
Acetocid; Acetosulfamin; Acetosulfamine; Albamine; Albucid; Alesten; Cetamide; Formosulfacetamide; Klaron; Oclucid; Ophthacet; Region; SULSTER; Sebizon; Solfacetamide; Steramide; Sulamyd; Sulfacet; Sulfacetamida; Sulfacetamidum; Sulfacetimide; Sulfacil; Sulfacyl; Sulfacylum; Sulfair; Sulfanilacetamide; Sulfanilazetamid; Sulphacetamide; Sulphacetamidum; Sulphasil; Sultrin; Urosulfon; Urosulfone; Isopto cetamide; Sodium sulamyd; Sodium sulfacetamide; Solfacetamide [DCIT]; Sulfacetamide Monosodium Salt; Sulfacetamide Sodium Usp; Sulfacetamide sodium; Sulfacetamide sodium anhydrous; Sulfanilazetamid [German]; Sulphacetamide sodium; Sulfair 15; A-500; Ak-Sulf; Bleph-10; Bleph-10 liquifilm; FML-S; I-Sulfacet; Isopto-Cetamide; Klaron (TN); N-Acetylsulfanilamide; N-Acetylsulfanilamine; N-Sulfanilylacetamide; N-Sulphanilylacetamide; N1-Acetylsulfanilamide; OP-Sulfa 30; Ocusulf-10; Ophthel-S; P-Aminobenzenesulfonacetamide; P-Aminobenzenesulfonoacetamide; Steri-Units Sulfacetamide; Sulf-10; Sulf-15; Sulfacel-15; Sulfacetamida [INN-Spanish]; Sulfacetamide [USAN:INN]; Sulfacetamidum [INN-Latin]; Sulfacyl (VAN); Sulfair-15; Sulten-10; N'-Acetylsulfanilamide; N(sup 1)-Acetylsulfanilamide; N(sup1)-Acetylsulfanilamide; Sulfacetamide (USP/INN); N-(4-Aminobenzenesulfonyl)acetamide; N-(4-Aminophenylsulfonyl)acetamide; N-(4-aminophenyl)sulfonylacetamide; N-Acetyl-4-aminobenzenesulfonamide; N-[(4-Aminophenyl)sulfonyl]acetamide; N-[(p-Aminophenyl)sulfonyl]acetamide; N(sup 1)-Acetyl-4-aminophenylsulfonamide; N-((4-Aminophenyl)sulfonyl)acetamide; N-((p-Aminophenyl)sulfonyl)acetamide
Therapeutic ClassAntibiotics
Cross-matching ID
PubChem CID
5320
ChEBI ID
CHEMBL63845
CAS Number
CAS 144-80-9
TTD Drug ID
D0M4VM
VARIDT Drug ID
DR00910
ACDINA Drug ID
D01448

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Coronavirus disease -1.67 4.50e-2 215/232 (92.67%) PIK3CD;RPL14;C3AR1;...
Cytokine-cytokine receptor interaction -1.67 4.48e-2 246/295 (83.39%) IL2;IL26;PF4;...
Steroid hormone biosynthesis -1.69 3.76e-2 43/61 (70.49%) CYP1B1;HSD11B2;AKR1C4;...
Fatty acid biosynthesis -1.70 3.60e-2 16/18 (88.89%) ACSL5;ACACB;FASN
Metabolism of xenobiotics by cytochrome P450 -1.73 2.63e-2 49/77 (63.64%) CYP1A1;ADH5;UGT2A3;...
Linoleic acid metabolism -1.75 2.46e-2 21/29 (72.41%) CYP2C8;PLA2G4A;PLA2G12A;...
NF-kappa B signaling pathway -1.76 2.56e-2 90/104 (86.54%) RELA;IRAK4;EDAR;...
Ferroptosis -1.77 2.23e-2 36/41 (87.8%) SAT1;TFRC;LPCAT3;...
Viral protein interaction with cytokine and cytokine re... -1.77 2.33e-2 84/100 (84%) IL2;PF4;CCR4;...
alpha-Linolenic acid metabolism -1.78 2.32e-2 17/25 (68%) ACAA1;PLA2G4A;PLA2G12A;...
Lysosome -1.80 2.15e-2 115/128 (89.84%) ATP6AP1;AP3S2;NPC2;...
Protein export -1.81 1.93e-2 17/23 (73.91%) HSPA5;SEC11A;SEC61A1;...
Steroid biosynthesis -1.82 1.64e-2 19/20 (95%) FDFT1;NSDHL;TM7SF2;...
ECM-receptor interaction -1.99 2.46e-3 80/88 (90.91%) COL1A1;TNXB;ITGAV;...
PPAR signaling pathway -2.02 3.07e-3 66/74 (89.19%) ACAA1;ACSL1;CYP7A1;...
Phagosome -2.03 4.09e-3 118/152 (77.63%) HLA-C;MBL2;MARCO;...
Complement and coagulation cascades -2.05 6.14e-3 76/85 (89.41%) F8;MBL2;CPB2;...
Malaria -2.15 0.00e+0 44/50 (88%) IL18;LRP1;CR1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H